The increasing use of monoclonal antibodies (MAbs) for disease diagnosis and therapy has created a class of patients at risk for systematic error in clinical testing due to interference by human anti-murine antibodies (HAMA). HAMA interference is often difficult to detect and can cause either an increase or a decrease in apparent concentrations of antigen present. We undertooka clinical study to test a HAMA-resistant enzyme immunoassay (EIA) format for carcinoembryonic antigen (CEA) determination. Using the Food and Drug Administration-approved CEA-EIA Monoclonal One-Step Assay (Abbott) with the addition of an acid/heat extraction of patients' specimens, we found that the resulting CEA values accurately reflected the patients' status. We demonstrated that the acid/heat-extracted specimens yield linear dilution curves and show analytical recoveries of added CEA in the range of 76-123% in HAMA-positive specimens and 86-103% in HAMA-negative specimens. The correlation of CEA values in extracted vs unextracted specimens from 184 patients and control subjects was 0.9963. The CEA detection limit of the assay was 1.6 g/L for the extracted samples. in the sera of such patients after this treatment has caused interference in laboratory methods used to measure carcinoembryonic antigen (CEA) (1) (2) (3) (4) (5) . This interference is often difficult to detect and has been shown to both increase and decrease measured CEA concentrations (1, 2, 4). CEA assays are used routinely to monitor cancer patients, and an increase in the CEA concentration is regarded as an early indicator of residual or recurrent colorectal cancer (6, 7). Because the presence or absence of llAMA in a given patient's serum is often unknown to the clinician, it is important that the assay used for CEA be resistant to this increasingly common interference.
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In this study, we used the Abbott (Abbott Park, IL) CEA-EIA Monoclonal One-Step Assay with an acid/heat extraction step (8) . This assay replaced the Abbott CEA-ELA Polyclonal Two-Step Assay, the production of which has been discontinued by the manufacturer. Although more cumbersome, the older assay format, because of its use of guinea pig and goat antisera plus an extraction step to precipitate interfering serum proteins, including immunoglobulins (8), was inherently more resistant to llAMA interference (1,4,8; Kinders et al., ma. submitted for publication). However, using the Monoclonal One-Step Assay with heatiacid extraction of the sample, we found that the CEA concentrations measured corresponded with patients' clinical status, whether HAMA was present in the sample or not. We first evaluated the Monoclonal One-Step Assay, with and without the extraction step, for reproducibility, dilution linearity, and analytical recovery experiments. Then we compared the performance of the acid! heat-extracted CEA-EIA Monoclonal One-Step with that of the standard kit format. Finally, normal subjects, patients with nonmalignant disease, and patients with known adenocarcinoma-who were both negative and positive for the presence of HAMA-were tested; some patients were monitored over time. Dilution linearity. Nine serum specimens, three each from lung, breast, and colon cancer patients, were tested undiluted and by dilution with zero standard without the extraction step. Then, in parallel, each specimen was acid/heat-extracted and assayed undiluted and after dilution with zero standard.
MaterIals and
All samples and dilutions were assayed by CEA-EIA Monoclonal One-Step (no. 3520) according to the manufacturer's directions.
Sensitivity.
Assay sensitivity, that is, the least detectable quantity of CEA, was determined by the formula by a single technologist, who used the assay in both the extracted and the unextracted formats separately. The sensitivity of the acid/heat-extracted assay was determined by multiplying the value obtained from the above calculation by 3, to account for the threefold dilution caused by the extraction step.
Analytical recovery. The recovery of CEA in the assay, with and without extraction, was evaluated by adding two known quantities of CEA to matched serum and EDTA-plasma samples from two normal individuals and to the assay zero standard, and then measuring CEA in both assay formats. The mean endogenous and enriched CEA values were calculated, and percent recoveries for both assay formats were determined as follows:
Percent recovery = The recovery of CEA was also evaluated with CEAsupplemented sera from colon cancer patients who had been treated with MAbs C110 or B72.3 (both 1g01,K) and who had subsequently developed measurable concentrations of HAMA of the IgG class in their sera. These HAMA-positive cancer patients' sera were supplemented with two different concentrations of CEA and then determined in both assay formats, unextracted and extracted.
HAMA Assay
Determination of serum HAMA titers (9) in the presence of antigen was performed in a 96-well plate with a bridging EIA format. For determination of anti-isotype reactivities, MAb B72.3 was used as the capture antibody ("coater") and murine MAb CilO IgG conjugated to horseradish peroxidase (HRPO; Sigma Chemical Co., St. Louis, MO; EC 1.11.1.7) was the probe. For determination of total HAMA, anti-CEA MAb CilO IgG was used as both the capture antibody and the HRPO-conjugated probe.
Immulon-11 (Dynatek Laboratories, Chantilly, VA) plates were coated with MAbs, 100 iLfwell, at a concentration of 2 g/L in pH 9.6 carbonate buffer, overnight at 2-8 #{176}C. Wells were then coated for 1 h at 37 #{176}C with 50 mmolfL phosphate-buffered saline, pH 7.4, containing 0.1 gIL bovine serum albumin, to block any nonspecific binding sites. Sera were diluted 1:10 in phosphatebuffered saline containing 50 mL of fetal bovine serum and 10 mg of gentamycin sulfate (Sigma) per liter, then serially diluted 1:2-1:1024 in the wells, with a final assay volume of 100 ML. Samples were incubated for 2 h at 37 #{176}C; the contents of the wells were then aspirated and the wells were washed 3 times. Then 100 ML of conjugate was added to each well. All MAbs were used as HRPO conjugates at a concentration of 2 mg/L in the phosphate-buffered saline/fetal bovine serum buffer. The plates were incubated for 2 h at 37#{176}C, then washed with distilled water, and developed by adding 100 ,AL of o-phenylenediamine . 2HC1 (Abbott). After 30 mm at room temperature, the development was stopped by adding 100 ML of H2S04 (0.5 mol/L) and the absorbance was read at 490 nm on a BioTektm (Wmooski, VT) microtiter plate reader. The reciprocal dilution of serum that gave an absorbance reading equal to 1.0 A in the assay was referred to as the HAMA titer.
Monoclonal
antibodies.
The MAbs used in this study were produced by standard methods from BALB/C mice with SP2/0 or NS-1 as fusion partners. Purification was on Protein A, essentially as described by Ey et al. (10) . Antibodies were conjugated with HRPO according to the method of Nakane and Kawaoi (11) . Antibody fragments were generated essentially as described by Parham (12) and Mage (13 The acid/heat extraction step was evaluated by analyzing 133 patients' samples chosen without conscious bias. These included 93 patients whose CEA values ranged from 0 to 12 gfL, 28 patients whose values were from 13 to 80 g/L, and 12 patients with CEA values ranging from 80 to 3000 g/L.
Patients/Clinical Specimens
Serum or plasma collected by standard procedures from a group of patients whose diagnosis was known and that had previously been assayed by the Food and Drug Administration (FDA)-approved Abbott CEA-EIA Two-Step Assay were included in this study. These specimens were used to assessthe ability of the One-
Step Assay with the acid/heat extraction step to accurately reflect CEA concentrations in patients' serum. Specimens in this group were from 20 normal subjects with no known malignancy or benign disease condition; 20 patients with nonmalignant disease, including cervical polyps, ulcerative colitis, pancreatitis, and diverticulitis; 33 patients with malignancies, including those of the colon, lung, breast, stomach, and pancreas; and 37 patients with various other malignancies. We also assayed samples from 38 cancer patients who had been tested for the presence of HAMA as described above, and were negative. These patients were then enrolled in an immunoscintigraphy trial in which they were injected with a single dose (5 mg intravenously) of anti-CEA MAb C110 labeled with 111 In (16). This procedure previously was shown to lead to the formation of HAMA in some patients ( 
Results

Removal of HAMA by Acid/Heat Extraction
To determine the degree of LlAMA removal that could be achieved by the acid/heat extraction method, we took two experimental approaches to the problem. (Figure IA) , but negative in the presence of CEA alone ( Figure 1B) . Titration of the CEA-contairnng plasma control by use of two CEAspecific MAbs (H8 and CilO) (19) is illustrated to indicate a positive result in the assay. decrease (90%) in signal in the HAMA assay alier the extraction. HAMA removal was apparently not quantitative: the midpoint titer after extraction was 40 (vs 360 originally) for specimen Al and 20 (vs 160) for specimen A2. We assumed that the reduction in titer did, however, reflect the LLAMA concentration, because the titrations of all specimens were linear at the midpoint (1.0 A4sc) of the curve.
Titration of plasma
Affinity purification of this specimen on Protein G (collecting the bound fraction from the plasma), followed by a secondaffinity step on a B72.3 column, yielded 1.96 g/L of human IgG (data not shown). These results suggested that acid/heat extraction could remove as much LlAMA as 1.76 gIL. Specimen A2, which had a lower HAMA titer than Al, showed a similar reduction in LLAMA signal in the plate ELISA.
Experiment
2.
The results from the above experiment indicated that acid/heat extraction was effective, but not quantitative in HAMA removal. We therefore tested whether HAMA remaining after extraction was sufficient to interfere in CEA determination. Specimens Al and A2 were supplemented with tissue culture CEA (42.3 g/L) and tested with the CEA-EIA Monoclonal One-Step Assay in extracted and unextracted formats; the control was zero standard containing added CEA. As shown in Table 1 , the quantity of LlAMA remaining after the extraction step did not interfere with measurement of a known quantity of CEA added to these plasma samples.
CEA Assay Validation
Sensitivity.
The detection limit of the unextracted kit was 0.53 gfL for the lot of kits tested. Sensitivity of the acid/heat-extracted assay was taken to be 3 times the calculated value for the unextracted kit (to account for specimen dilution): 1.6 gfL.
Reproducibility studies. Intra-and interassay CVs for six different CEA concentrations measured by the CEA-EIA Monoclonal One-Step Assay with the acid/heat extraction step were 10% except for the lowest-concentration CEA specimen. The intra-assay CVs for six replicates with mean concentrations of 2-57 gfL ranged from 4% to 8%. These replicates were assayed by a single technologist on a single day. The interassay (C) Titration of patient A plasma (0, t as In panel A) after the acid/heat extraction step used in the CEA assay validation described in this paper.
HAMA contents are reduced by >85% for both specimens Specimentitrationcurvesshownin Fig. 1A b C iculated as described in text CVs were calculated from the results of eight runs (a total of 48 observations) done by two technologists over a 4-clay period. The CVs ranged from 6% to 8% for mean CEA concentrations of 2-57 g/L. The intra-and interassay CVs for the lowest CEA concentration (1.1 g/L) were 12% and 14%, respectively.
Dilution linearity and recovery. Linear dilutions of the extracted and unextracted data were first analyzed by linear regression. Specimens from patients with diagnosed colon, breast, or lung cancer (three different patients for each disease, n = 9) all yielded correlation coefficients >0.99 for both assay formats.
We then tested the linearity of dilution of the extracted format of the assay by fitting the raw assay concentration data from each series to a second-order polynomial equation with the reciprocal of the dilution as the dependent variable. Plots of the resulting data indicated that all nine specimens exhibited linear dilutions. The probabilities that a second-order coefficient was not needed to explain any deviation of the data from expected results ranged from 0.0001 to 0.0729 for four specimens and from 0.1276 to 0.1977 for three additional specimens. One specimen had too few dilutions to be analyzed by this method; the remleining specimen yielded a seemingly high value of 0.4508, although the maximum deviation between the polynomial and straight-line fit of the data for this specimen was 1 Table 2 shows the results of analytical recovery studies of CEA in sera from HAMA-positive cancer patients with and without extraction. Recovery of CEA without extraction ranged from 0% to 14&9% (mean recovery of 66%); in these same supplemented HAMA-positive cancer-patient sera treated with the acid/heat extraction step, recovery of CEA ranged from 76.1% to 122.8% (mean 101%). The increased range of values in this format was principally associated with the lower quantity of CEAs added (5.52 g/L), reflecting the loss of precision in the assay at low CEA concentrations associated with the threefold dilution that accompanies the extraction step. 
Evaluationof Acid/Heat ExtractionProcedure
The performance of the acid/heat extraction step (y) was tested against the unextracted assay format (x) for samples from 184 individuals that were llAMA-free ( The llAMA-negative patients' results (Figure 2) demonstrate that, in the absence of llAMA, CEA assay results are similar whether the assay includes the acid/heat pretreatment or not. However, Figure 3 shows that, without the acid/heat extraction, the CEA value would be significantly misleading in some patients with llAMA titers. Figure 3A depicts a tracking series for a patient (SKO7, peak MAMA titer of 1:30) from presurgery through a 7-month follow-up. In this case, cancer recurrence was masked at the 210th day postaurgery in the CEA-EIA Monoclonal One-Step Assay performed without acid/heat extraction. This false-negative result was not a problem for either assay when the extraction procedure was included. Confirmation of disease recurrence was obtained by physical examination and computerized tomographic scan. For the patient tracked in Figure 3B (SK11), the increase in CEA concentration reflects recurring cancer, as diagnosed by computerized tomography. In the first 90 days after injection of the antitumor MAb, the patient did not exhibit a HAMA response. After reujection of the MAb, the patient's MAMA content rose to a titer <1:100. The much higher CEA measurement by the unmodified assay at 300 days corresponded to the appearance at the same time of a positive HAMA titer in that patient. In sharp contrast to patient SKO7, the results here were falsely positive, even though both patients were imaged with the same MAb, C 110. The patient received chemotherapy. Patient UM1O ( Figure 3C ) remained ambulatory and was diagnosed in a stable disease state, not in remission. The effects of HAMA in this patient (with a peak titer of 1:471) were a false-negative CEA value when assayed by the CEA-EIA Monoclonal One-Step Assay without the heat/extraction method. Our study expands these data substantially and provides an independent quantitative assessment of assay performance. For the patients in the present study who remained MAMA-negative and were monitored over time, the results of the CEA-EIA Monoclonal One-Step Assay, whether the extraction step was used or not, essentially agreed with both the previously used assay, the CEA-EIA Polyclonal Two-Step, and with the actual clinical status of the patient according to the physician's report. However, for six of the seven patients in the tracking study who developed positive titers for HAMA, the assays did not agree. The Monoclonal One-Step Assay results for these six patients differed not only from the results by the same assay done with the extraction step and by the previously used Polyclonal Two-Step Assay but also with the observed clinical condition of the patient (see Figure 3 ).
In addition, in this and other (20) patient populations, it has been observed that these MAMA titers can be very long lasting (>10 months), even after a single injection of MAb. Other investigators (23) have reported that MAMA titers appear to cycle up and down over time.
These observations are consistent with the history of patients SK11 and UM1O (Figure 3 and other 
